Long-lasting response to erlotinib in lung cancer
Author Information
Author(s): Michael Copeman
Primary Institution: Northern Beaches Cancer Service, Sydney, Australia
Hypothesis
Can erlotinib provide a prolonged response in patients with advanced lung adenocarcinoma who refuse chemotherapy?
Conclusion
Erlotinib can lead to significant radiological and symptomatic improvement in patients with advanced NSCLC who are unsuitable for chemotherapy.
Supporting Evidence
- The patient had a partial response to erlotinib after 7 months.
- Erlotinib was well tolerated with manageable side effects.
- The patient maintained daily activities during treatment.
Takeaway
A woman with lung cancer felt better and had less pain after taking a medicine called erlotinib instead of chemotherapy.
Methodology
Case report detailing the patient's treatment and response to erlotinib.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
58-year-old non-smoking female of Philippine origin.
Statistical Information
Confidence Interval
95% confidence intervals 0.58–0.85
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website